Analysis Group
Industry / private company
Location:
Los Angeles, CA,
United States (USA) (US)
ISNI: 0000000446609516
ROR: https://ror.org/044jp1563
Cost-effectiveness of pembrolizumab plus chemotherapy as first-line treatment in PD-L1-positive metastatic triple-negative breast cancer (2022)
Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou ZY, Hu P, et al.
Journal article
COST EFFECTIVENESS OF PEMBROLIZUMAB COMBINED WITH CHEMOTHERAPY VS. CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR METASTATIC TNBC THAT EXPRESSES PD-L1 IN THE UNITED STATES (2022)
Huang M, Fasching P, Haiderali A, Pan W, Gray E, Zhou J, Hu PH, et al.
Conference contribution
Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis (2020)
Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey SD, Briggs A, et al.
Journal article, Review article
Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer (2020)
Huang M, O'Shaughnessy J, Zhao J, Haiderali A, Cortes J, Ramsey S, Briggs A, et al.
Journal article
Meta-analysis on association of pathological complete response with long-term survival outcomes in triple-negative breast cancer (2019)
Fasching P, Huang M, Cortes J, Zhao J, O'Shaughnessy J, Hu P, Haiderali A, et al.
Conference contribution